Similar articles

• Transplant and Nontransplant Salvage Therapy in Pediatric Relapsed or Refractory Hodgkin Lymphoma: The EuroNet-PHL-R1 Phase 3 Nonrandomized Clinical Trial.

  Daw S, Claviez A, Kurch L, Stoevesandt D, Attarbaschi A, Balwierz W, Beishuizen A, Cepelova M, Ceppi F, Fernandez-Teijeiro A, Fosså A, Georgi TW, Hjalgrim LL, Hraskova A, Leblanc T, Mascarin M, Pears J, Landman-Parker J, Prelog T, Klapper W, Ramsay A, Kluge R, Dieckmann K, Pelz T, Vordermark D, Körholz D, Hasenclever D, Mauz-Körholz C. Daw S, et al. JAMA Oncol. 2025 Mar 1;11(3):258-267. doi: 10.1001/jamaoncol.2024.5636. JAMA Oncol. 2025. PMID: 39745682 Clinical Trial.
• High-dose therapy with autologous stem cell transplantation versus chemotherapy or immuno-chemotherapy for follicular lymphoma in adults.

  Schaaf M, Reiser M, Borchmann P, Engert A, Skoetz N. Schaaf M, et al. Cochrane Database Syst Rev. 2012 Jan 18;1(1):CD007678. doi: 10.1002/14651858.CD007678.pub2. Cochrane Database Syst Rev. 2012. PMID: 22258971 Free PMC article.
• Population Pharmacokinetics of Epcoritamab Following Subcutaneous Administration in Relapsed or Refractory B Cell Non-Hodgkin Lymphoma.

  Li T, Gibiansky L, Parikh A, van der Linden M, Sanghavi K, Putnins M, Sacchi M, Feng H, Ahmadi T, Gupta M, Xu S. Li T, et al. Clin Pharmacokinet. 2025 Jan;64(1):127-141. doi: 10.1007/s40262-024-01464-2. Epub 2024 Dec 21. Clin Pharmacokinet. 2025. PMID: 39708278 Clinical Trial.
• Current approaches to the management of pediatric Hodgkin lymphoma.

  Freed J, Kelly KM. Freed J, et al. Paediatr Drugs. 2010 Apr 1;12(2):85-98. doi: 10.2165/11316170-000000000-00000. Paediatr Drugs. 2010. PMID: 20218745 Review.
• Salvage treatment for relapsed/refractory Hodgkin lymphoma: role of allografting, brentuximab vedotin and newer agents.

  Martino M, Festuccia M, Fedele R, Console G, Cimminiello M, Gavarotti P, Bruno B. Martino M, et al. Expert Opin Biol Ther. 2016;16(3):347-64. doi: 10.1517/14712598.2015.1130821. Epub 2016 Feb 6. Expert Opin Biol Ther. 2016. PMID: 26652934